Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2008;118:576-585
Published online before print July 7, 2008, doi: 10.1161/CIRCULATIONAHA.108.190186
Free Article
This Article
Free upon publication Free Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
118/5/576    most recent
CIRCULATIONAHA.108.190186v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kahn, R.
Right arrow Articles by Eddy, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kahn, R.
Right arrow Articles by Eddy, D.

(Circulation. 2008;118:576-585.)
© 2008 American Heart Association, Inc.


Special Report

The Impact of Prevention on Reducing the Burden of Cardiovascular Disease

Richard Kahn, PhD; Rose Marie Robertson, MD, FAHA; Robert Smith, PhD; David Eddy, MD, PhD

From the American Diabetes Association, Alexandria, Va (R.K.); American Heart Association, Dallas, Tex (R.M.R.); American Cancer Society, Atlanta, Ga (R.S.); and Archimedes, Inc, San Francisco, Calif (D.E.).

Correspondence to Richard Kahn, PhD. E-mail rkahn{at}diabetes.org

Objective— Cardiovascular disease (CVD) is prevalent and expensive. While many interventions are recommended to prevent CVD, the potential effects of a comprehensive set of prevention activities on CVD morbidity, mortality, and costs have never been evaluated. We therefore determined the effects of 11 nationally recommended prevention activities on CVD-related morbidity, mortality, and costs in the United States.

Research Design and Methods— We used person-specific data from a representative sample of the US population (National Health and Nutrition Education Survey IV) to determine the number and characteristics of adults aged 20-80 years in the United States today who are candidates for different prevention activities related to CVD. We used the Archimedes model to create a simulated population that matched the real US population, person by person. We then used the model to simulate a series of clinical trials that examined the effects over the next 30 years of applying each prevention activity one by one, or altogether, to those who are candidates for the various activities and compared the health outcomes, quality of life, and direct medical costs to current levels of prevention and care. We did this under two sets of assumptions about performance and compliance: 100% success for each activity and lower levels of success considered aggressive but still feasible.

Results— Approximately 78% of adults aged 20-80 years alive today in the United States are candidates for at least one prevention activity. If everyone received the activities for which they are eligible, myocardial infarctions and strokes would be reduced by 63% and 31%, respectively. If more feasible levels of performance are assumed, myocardial infarctions and strokes would be reduced 36% and 20%, respectively. Implementation of all prevention activities would add {approx}221 million life-years and 244 million quality-adjusted life-years to the US adult population over the coming 30 years, or an average of 1.3 years of life expectancy for all adults. Of the specific prevention activities, the greatest benefits to the US population come from providing aspirin to high-risk individuals, controlling pre-diabetes, weight reduction in obese individuals, lowering blood pressure in people with diabetes, and lowering LDL cholesterol in people with existing coronary artery disease (CAD). As currently delivered and at current prices, most prevention activities are expensive when considering direct medical costs; smoking cessation is the only prevention strategy that is cost-saving over 30 years.

Conclusions— Aggressive application of nationally recommended prevention activities could prevent a high proportion of the CAD events and strokes that are otherwise expected to occur in adults in the United States today. However, as they are currently delivered, most of the prevention activities will substantially increase costs. If preventive strategies are to achieve their full potential, ways must be found to reduce the costs and deliver prevention activities more efficiently.




This article has been cited by other articles:


Home page
StrokeHome page
L. Arab, W. Liu, and D. Elashoff
Green and Black Tea Consumption and Risk of Stroke: A Meta-Analysis
Stroke, May 1, 2009; 40(5): 1786 - 1792.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
J. Sanz, P. R. Moreno, and V. Fuster
The year in atherothrombosis.
J. Am. Coll. Cardiol., April 14, 2009; 53(15): 1326 - 1337.
[Full Text] [PDF]


Home page
Circ Cardiovasc Qual OutcomesHome page
Heart Protection Study Collaborative Group
Statin Cost-Effectiveness in the United States for People at Different Vascular Risk Levels
Circ Cardiovasc Qual Outcomes, March 1, 2009; 2(2): 65 - 72.
[Abstract] [Full Text] [PDF]